Supportive Care in Cancer

, Volume 13, Issue 1, pp 70–72

Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)

Authors

    • Division of Thoracic Oncology, Department of MedicineMemorial Sloan-Kettering Cancer Center and the Weil Medical College of Cornell University
    • Memorial Sloan-Kettering Cancer Center
  • Mark G. Kris
    • Division of Thoracic Oncology, Department of MedicineMemorial Sloan-Kettering Cancer Center and the Weil Medical College of Cornell University
  • Jorge E. Gomez
    • Division of Thoracic Oncology, Department of MedicineMemorial Sloan-Kettering Cancer Center and the Weil Medical College of Cornell University
  • Marc B. Feinstein
    • Division of Pulmonary Medicine, Department of MedicineMemorial Sloan-Kettering Cancer Center and the Weil Medical College of Cornell University
Short Communication

DOI: 10.1007/s00520-004-0717-z

Cite this article as:
Milton, D.T., Kris, M.G., Gomez, J.E. et al. Support Care Cancer (2005) 13: 70. doi:10.1007/s00520-004-0717-z

Abstract

Bronchorrhea is a condition in which voluminous sputum is produced daily, typically seen with bronchioloalveolar cell carcinoma (BAC). Unless the underlying cancer can be controlled, bronchorrhea causes substantial symptomatic distress. We report two cases of bronchorrhea associated with advanced BAC successfully treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib. Prompt resolution of these patients’ bronchorrhea, dyspnea, and supplemental oxygen requirements are detailed. Given the limited success of alternative interventions, a trial of gefitinib should be considered for patients with bronchorrhea secondary to BAC.

Keywords

BACBronchorrheaEGFRGefitinib

Copyright information

© Springer-Verlag 2004